within Pharmacolibrary.Drugs.ATC.L;

model L01XK02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.73,
    Cl             = 0.0002866666666666667,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 1.08,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013616666666666666,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.457,
    k12             = 19.1,
    k21             = 19.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XK02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Niraparib is an oral, selective poly(ADP-ribose) polymerase (PARP) inhibitor, primarily used as an anti-cancer agent for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is an approved drug for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data from adult female ovarian cancer patients after oral administration of niraparib.</p><h4>References</h4><ol><li><p>Chryssafidis, P, et al., &amp; Macheras, P (2022). Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models. <i>Pharmaceutical research</i> 39(4) 691–701. DOI:<a href=&quot;https://doi.org/10.1007/s11095-022-03230-0&quot;>10.1007/s11095-022-03230-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35378697/&quot;>https://pubmed.ncbi.nlm.nih.gov/35378697</a></p></li><li><p>van Andel, L, et al., &amp; Beijnen, JH (2018). Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a . <i>Cancer chemotherapy and pharmacology</i> 81(1) 39–46. DOI:<a href=&quot;https://doi.org/10.1007/s00280-017-3455-x&quot;>10.1007/s00280-017-3455-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29043410/&quot;>https://pubmed.ncbi.nlm.nih.gov/29043410</a></p></li><li><p>Yonemori, K, et al., &amp; Yamamoto, N (2021). The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. <i>Japanese journal of clinical oncology</i> 51(5) 693–699. DOI:<a href=&quot;https://doi.org/10.1093/jjco/hyab013&quot;>10.1093/jjco/hyab013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621324/&quot;>https://pubmed.ncbi.nlm.nih.gov/33621324</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XK02;
